SILO News & Events

Silo Pharma announced that the European Patent Office has issued a Rule 71 communication indicating its intent to grant a patent for an European patent application titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress" that the company has an exclusive license from Columbia University. The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders using selected serotonin 4 receptor agonists - a differentiated approach targeting pathways associated with stress resilience rather than just symptom management.

Silo Pharma announced that its board of directors has authorized a share repurchase program to acquire up to $1M of the company's common stock. The company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as reported in its quarterly report for the period ended September 30, 2025.

Silo Pharma announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder, PTSD. The allowed application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," strengthens Silo's growing intellectual-property portfolio in stress-modulating therapeutics and supports the Company's strategy to protect its core scientific innovations in key global markets.